The estimated Net Worth of Judith V Klimovsky is at least $83.8 Tisíc dollars as of 3 January 2023. Judith Klimovsky owns over 60,414 units of Bellicum Pharmaceuticals Inc stock worth over $8,230 and over the last 6 years he sold BLCM stock worth over $0. In addition, he makes $75,550 as Independent Director at Bellicum Pharmaceuticals Inc.
Sign up
Judith Klimovsky BLCM stock SEC Form 4 insiders trading
Judith has made over 3 trades of the Bellicum Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 60,414 units of BLCM stock worth $4,516 on 3 January 2023.
The largest trade he's ever made was exercising 60,414 units of Bellicum Pharmaceuticals Inc stock on 3 January 2023 worth over $4,516. On average, Judith trades about 10,009 units every 33 days since 2018. As of 3 January 2023 he still owns at least 110,098 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Judith Klimovsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Judith Klimovsky biography
Dr. Judith Klimovsky M.D. serves as Independent Director of the Company. Dr. Klimovsky has served as a member of our Board since December 2018. Since February 2017, Dr. Klimovsky has served as the Executive Vice President & Chief Development Officer of Genmab A/S, a public international biotechnology company developing antibody therapeutics for cancer, where she leads the company’s product development efforts. Dr. Klimovsky previously held a number of senior positions at Novartis AG, a public international pharmaceutical company, including Senior Vice President, Head of Clinical Development from May 2015 to February 2017, Vice President, Global Program Head from April 2013 to April 2015, and Executive Medical Director from May 2009 to April 2013. Prior to joining Novartis, Dr. Klimovsky held successively senior positions at Bristol-Myers Squibb and Merck, where she led and contributed to the clinical development of key cancer drugs. Previously, Dr. Klimovsky served in various hematology clinical practice positions in Buenos Aires, Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires University School of Medicine. Our Board believes that Dr. Klimovsky brings extensive leadership experience in drug development, particularly in the areas of oncology and hematology that qualify her to serve on our Board.
What is the salary of Judith Klimovsky?
As the Independent Director of Bellicum Pharmaceuticals Inc, the total compensation of Judith Klimovsky at Bellicum Pharmaceuticals Inc is $75,550. There are 8 executives at Bellicum Pharmaceuticals Inc getting paid more, with Richard Fair having the highest compensation of $1,732,890.
How old is Judith Klimovsky?
Judith Klimovsky is 63, he's been the Independent Director of Bellicum Pharmaceuticals Inc since 2018. There are no older and 15 younger executives at Bellicum Pharmaceuticals Inc.
What's Judith Klimovsky's mailing address?
Judith's mailing address filed with the SEC is 614 MCKINLEY PLACE NE, , MINNEAPOLIS, MN, 55413.
Insiders trading at Bellicum Pharmaceuticals Inc
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... a Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
What does Bellicum Pharmaceuticals Inc do?
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
What does Bellicum Pharmaceuticals Inc's logo look like?
Complete history of Judith Klimovsky stock trades at Bellicum Pharmaceuticals Inc a Bio-Techne Corp
Bellicum Pharmaceuticals Inc executives and stock owners
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Richard Fair,
President, Chief Executive Officer, Director -
Richard A. Fair,
Pres, CEO & Director -
Shane Ward,
Corporate Secretary, Chief Legal and Strategy Officer -
Charity D. Scripture M.S., Pharm.D.,
Chief Devel. Officer -
James Brown,
Independent Chairman of the Board -
Jon Stonehouse,
Independent Director -
Reid Huber,
Independent Director -
Stephen Davis,
Independent Director -
Judith Klimovsky,
Independent Director -
James Daly,
Independent Director -
David Strauss,
Corporate Controller -
Aaron Foster,
Senior Vice President, Head of Research -
Atabak Mokari,
Chief Financial Officer -
Charity Scripture,
Chief Devel. Officer -
Dr. Aaron E. Foster,
Head of Research & Sr. VP -
Dr. Alan K. Smith Ph.D.,
Chief Scientific Officer -
Joseph Senesac,
Sr. VP of Technical Operations & Quality -
Charles S. Grass,
Principal Accounting Officer -
Alan A Musso,
CFO and Treasurer -
Thomas J. Farrell,
President and CEO -
Frank B. Mc Guyer,
Director -
Alan K. Smith,
EVP, Technical Operations -
Ken Moseley,
Vice President -
Kevin M. Slawin,
CMO and CTO -
Bros. Advisors Lpbaker Feli...,
-
Peter L. Hoang,
Sr. VP of Bus. Development -
Annemarie Moseley,
Chief Operating Office and EVP -
Rosemary Y. Williams,
VP, Finance & PAO -
Gregory S. Naeve,
Chief Business Officer -
Bros. Advisors Lp Baker Bro...,
-
Edmund Harrigan,
Director -
William Grossman,
Sr. VP, Chief Medical Officer -
David M. Spencer,
Chief Scientific Officer -
Jr Joseph Paul Woodard,
SVP Clinical & Medical Affairs -
Joseph Senesac,
VP of Manufacturing -
Investments Ltd. Mc Guyer,
10% owner -
Ventures Llc Remeditex,
10% owner -
Charity Scripture,
Chief Development Officer -
Bros. Advisors Lpbaker Juli...,